Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Rating) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,900 shares, a growth of 18.8% from the November 30th total of 1,600 shares. Based on an average trading volume of 3,700 shares, the short-interest ratio is currently 0.5 days.
Algernon Pharmaceuticals Trading Down 3.2 %
Shares of AGNPF stock opened at $1.63 on Friday. The business's 50 day simple moving average is $1.98 and its 200 day simple moving average is $2.77. Algernon Pharmaceuticals has a one year low of $1.52 and a one year high of $9.28.
Get
Algernon Pharmaceuticals alerts:
About Algernon Pharmaceuticals
(Get Rating)
Algernon Pharmaceuticals Inc operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia.
Read More
- Get a free copy of the StockNews.com research report on Algernon Pharmaceuticals (AGNPF)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for Algernon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Algernon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
阿尔杰农制药公司(场外交易市场代码:AGNPF-GET Rating)是空头股数12月份实现显著增长的目标。截至12月15日,空头股数共有1,900股,较11月30日的1,600股增长18.8%。以平均成交量3,700股计算,目前短息比率为0.5天。
Algernon制药公司股价下跌3.2%
AGNPF股票上周五开盘报1.63美元。该业务的50日简单移动均线切入位为1.98美元,200日简单移动均线切入位为2.77美元。Algernon PharmPharmticals的一年低点为1.52美元,一年高位为9.28美元。
到达
阿尔杰农制药公司警报:
关于Algernon制药公司
(获取评级)
Algernon制药公司是一家临床阶段药物开发公司。它集中在加拿大和澳大利亚与新冠肺炎相关的非酒精性脂肪性肝炎、慢性肾脏疾病、炎症性肠道疾病、特发性肺纤维化、慢性咳嗽和急性肺损伤等领域。
阅读更多内容
- 免费获取StockNews.com关于Algernon制药的研究报告(AGNPF)
- MarketBeat:回顾一周12/26-12/30
- 科技狗:是时候咬一口这些股票了
- 这笔收购会让微软成为熊市买入者吗?
- 你应该热身到Generac股票过冬吗?
- 金塔拉治疗公司是一颗隐藏的宝石吗?
获得Algernon PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Algernon制药和相关公司的最新新闻和分析师评级的每日简要摘要。